Intellia Therapeutics, Inc.

Contributing Author

Recent Articles by Intellia Therapeutics, Inc.

Jul-07	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jun-15	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress NTLA GlobeNewswire
Jun-05	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
May-18	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting NTLA GlobeNewswire
May-08	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
May-06	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire